TriSalus Life Sciences Reports Third Quarter 2026 Results

On November 10, 2026 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, reported financial results for the quarter ended September 30, 2026, and provided an operational update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The third quarter marked an important period of growth and expansion for TriSalus – we drove double-digit year-over-year growth and received FDA clearance for TriNav Advance, which enables Pressure-Enabled Drug Delivery to small distal vessels through the microcatheter of the physician’s choice. This clearance allows us to address the full range of vessels encountered in liver embolization procedures going forward," said Mary Szela, President and Chief Executive Officer of TriSalus.

"Looking ahead, we believe we are well positioned for 2027. We more than doubled our commercial footprint over the first half of the year, and although our team productivity has ramped slightly slower than anticipated, our representatives continue to educate and drive further TriNav utilization as they build and strengthen relationships with interventional radiologists. Combined with the launch of TriNav Advance, expanded access to office-based labs through the new G-code, and continued cost discipline, we believe we have laid the foundation for continued growth in 2027 and beyond."

Recent Business Highlights

Received FDA clearance for TriNav Advance, which enables PEDD to small distal vessels through the microcatheter of the physician’s choice.
In the calendar year 2027 Hospital Outpatient Prospective Payment System ("OPPS") final rule, the Centers for Medicare & Medicaid Services ("CMS") finalized the reassignment of HCPCS code C8004 from APC 5193 to APC 5194, aligning it with C9797, which is already assigned to APC 5194. Based on the final rule, the national Medicare payment rate for procedures billed under C8004 will increase from approximately $11,794 to approximately $20,910, effective January 1, 2027.
Additionally, CMS published its calendar year 2027 Physician Fee Schedule final rule, establishing national payment for HCPCS code G0577, vascular embolization using a pressure-generating catheter in the office-based lab setting. Effective January 1, 2027, the total national office payment is approximately $13,800 per procedure, extending reimbursement for PEDD.
Achieved the enrollment cutoff required for the interim analysis of the PROTECT registry in thyroid artery embolization; the Company remains on track to deliver the first multi-center U.S. data on thyroid artery embolization in the first quarter of 2027.
Financial Results for Q3 2026

Revenue from the sale of the TriNav system was $12.9 million for the three months ended September 30, 2026, an increase of 11.3% compared to the same period in 2025. The increase in revenue was primarily due to an increase in TriNav units sold.
Gross margins were 86.2% for the three months ended September 30, 2026, compared to 83.5% for the same period in 2025. The year-over-year increase in gross margin was primarily due to a reduction in cost per TriNav unit.
Operating losses were $7.7 million for the three months ended September 30, 2026, compared to losses of $9.0 million for the same period in 2025. The decrease in operating losses was primarily driven by improved gross margins, lower research and development expenses and lower general and administrative expenses, partially offset by higher sales and marketing expenses related to our investment in marketing and our sales organization expansion.
Net loss attributable to common stockholders was $8.9 million for the three months ended September 30, 2026, compared to a net loss of $41.3 million for the same period in 2025. This change is primarily driven by the conversion of our preferred stock to common stock during the third quarter of 2025, resulting in approximately $30.5 million of net loss attributable to common stockholders. The current period includes $0.1 million of non-cash net gains related to changes in the fair value of various derivatives for the three months ended September 30, 2026, compared to net losses of $0.4 million for the same period in 2025. The basic and diluted loss per share for the three months ended September 30, 2026 was $0.15, compared to $0.96 for the same period in 2025.
The non-GAAP measure of adjusted EBITDA is shown in the table below as the Company believes it is an important measure of performance. Adjusted EBITDA losses were $4.7 million for the three months ended September 30, 2026, compared to losses of $5.4 million for the same period in 2025. The decrease in adjusted EBITDA losses were primarily driven by improved gross margins, lower research and development and lower general and administrative expenses, partially offset by increased sales and marketing expenses.
On September 30, 2026, cash and cash equivalents totaled $41.1 million. The Company raised $46.0 million in gross proceeds in the first quarter from an equity offering.
2026 Financial Guidance

The Company is updating its full-year 2026 revenue guidance to $46 million to $48 million, representing growth of approximately 2% to 6% compared to full year 2025.

Conference Call & Webcast

The Company will host a conference call and webcast today at 8:30 AM eastern time to discuss its financial results for the quarter ended September 30, 2026. Those interested in listening should register online by visiting investor relations section of TriSalus’ website. Participants are encouraged to register more than 15 minutes before the start of the call. A replay will also be available on the website following the event.

(Press release, TriSalus Life Sciences, NOV 10, 2026, View Source [SID1234674591])

Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

On November 10, 2026 Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, reported its operational and financial results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain positive experience with the therapy, and supported by real-world data reported through the ROCCA consortium. Importantly, we also continue to improve the gross margin, with strong execution on manufacturing efficiency initiatives," said Dr. Christian Itin, Chief Executive Officer of Autolus.

Dr. Itin added, "AUCATZYL’s performance in adult r/r B-ALL is a key near-term value driver. Longer term, we believe expanding obe-cel across all stages of ALL and into autoimmune indications offers meaningful opportunities for scalable growth, leveraging its favorable profile and Autolus’ proven manufacturing and commercial capabilities. We look forward to autoimmune program data presentations at upcoming key medical meetings."

Product and Pipeline Updates:

AUCATZYL
Autolus reported net product revenue of $41.2 million for the three months ended September 30, 2026, compared to $21.1 million for the same period the prior year. Net revenues were primarily driven by increasing product demand both within existing treatment centers and expansion into new centers, supplemented by contribution from UK sales.
Obe-cel in pediatric r/r B-ALL
The Phase 2 portion of the ongoing CATULUS trial of obe-cel in pediatric patients with relapsed or refractory B-cell precursor ALL (r/r B-ALL) is on track and data are expected to be reported at the end of 2027.
Obe-cel in lupus
Updated data from the ongoing Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) will be presented in a poster at the American College of Rheumatology (ACR) Annual Meeting, today, November 10, 2026. These data will include safety and efficacy results with up to 25 months follow-up in adult patients and ≥3 months follow-up in adolescent patients.
LUMINA, the pivotal Phase 2 study of obe-cel in patients with refractory lupus nephritis (LN) continues enrolling in five countries and the Company expects to report data in 2028.
On September 9, 2026, the U.S. Food and Drug Administration (FDA) granted regenerative medicine advanced therapy (RMAT) designation to obe-cel for the treatment of SLE and LN. RMAT is designed to accelerate the development and regulatory review of regenerative medicine therapies, including cell therapies, intended to treat serious or life-threatening diseases.
Obe-cel in progressive multiple sclerosis
KOL feedback at the ACTRIMS/ECTRIMS meeting in late October emphasized that initial clinical activity and biomarker data seen across CAR T programs are encouraging but will require longer follow up to judge the clinical benefit in progressive MS patients. Considering this feedback, Autolus plans to move the first data presentation to the ECTRIMS Global meeting in October 2027. At that time, the Company expects to have 12 months or more follow-up for the initial 12 patients dosed, and data in up to 24 patients total. Lymphodepletion with both FLu/Cy as well as bendamustine is being evaluated.

AUTO8 in Light-Chain Amyloidosis
The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at ASH (Free ASH Whitepaper) in December 2026.

Outlook:
Autolus now expects full-year 2026 AUCATZYL net product revenue to be at or exceeding the upper end of $150 million from the prior guidance.

Based on current operating plans, including anticipated AUCATZYL net revenues and proceeds of the combined first and second tranches totaling $100 million from the Perceptive credit facility, Autolus expects that its current and projected cash, cash equivalents and marketable securities will be sufficient to fund the Company’s operations into Q2 2028.

Summary of Anticipated News Flow:

Longer-term follow up data from CARLYSLE trial in patients with severe refractory systemic lupus erythematosus ACR 2026
November 10, 2026
Initial clinical data from ALARIC Phase 1 trial in patients with light-chain amyloidosis ASH 2026
December 12, 2026
Initial clinical data from BOBCAT Phase 1 trial in patients with progressive MS October 2027
Phase 2 data from CATULUS trial in patients with pediatric r/r B-ALL By year-end 2027
Phase 2 data from LUMINA trial in patients with LN In 2028

Financial Results for the Quarter Ended September 30, 2026
Product revenue, net increased to $41.2 million for the three months ended September 30, 2026, compared to $21.1 million the same period in 2025.

Cost of sales decreased to $17.9 million for the three months ended September 30, 2026, compared to $28.6 million the same period in 2025. Gross margin1 was 57% in the third quarter of 2026, increasing from 55% in the second quarter of 2026, and a negative gross margin in the same period in 2025. The improvement in gross margin over the prior year was primarily driven by a reduction in manufacturing cost per batch, reflecting increased volumes and the ongoing operational efficiency initiatives, and lower inventory reserves and write-offs compared to the same period in the prior year.

Research and development expenses increased to $30.9 million for the three months ended September 30, 2026, compared to $27.9 million in the same period in 2025. This change was primarily due to an increase in clinical manufacturing supply costs driven by clinical development activities, partially offset by a decrease in salaries and other employment-related costs.

Selling, general and administrative expenses decreased to $35.9 million for the three months ended September 30, 2026, compared to $36.3 million in the same period in 2025. This decrease was primarily due to salaries, other employment-related costs and professional fees supporting commercialization activities in the US and UK.

Loss from operations for the three months ended September 30, 2026, was $43.5 million, as compared to $71.6 million for the same period in 2025.

Net loss was $55.1 million for the three months ended September 30, 2026, compared to $79.1 million for the same period in 2025. Basic and diluted net loss per ordinary share for the three months ended September 30, 2026, was $(0.21), compared to basic and diluted net loss per ordinary share of $(0.30) for the same period in 2025.

Cash, cash equivalents and marketable securities at September 30, 2026, totaled $248.4 million, as compared to $201.6 million at June 30, 2026. The increase was primarily driven by net cash inflows from the senior secured note facility from Perceptive Advisors.

Selected Consolidated Statements of Operations and Comprehensive Loss Data
(In thousands, except share and per share amounts)

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026
2025
2026
2025
Revenue:
Product revenue, net $ 41,238 $ 21,144 $ 113,128 $ 51,049
License revenue — 50 17 50
Total revenue, net 41,238 21,194 113,145 51,099
Cost and operating expenses:
Cost of sales (17,927 ) (28,643 ) (62,963 ) (71,039 )
Research and development expenses, net (30,900 ) (27,892 ) (80,008 ) (82,056 )
Selling, general and administrative expenses (35,946 ) (36,280 ) (117,060 ) (96,082 )
Loss from operations (43,535 ) (71,621 ) (146,886 ) (198,078 )
Other (expense) income:
Total other (expenses) income, net (12,045 ) (6,965 ) (18,075 ) 4,037
Net loss before income tax (55,580 ) (78,586 ) (164,961 ) (194,041 )
Income tax benefit (expense) 489 (532 ) (839 ) (3,155 )
Net loss (55,091 ) (79,118 ) (165,800 ) (197,196 )
Other comprehensive income (loss):
Foreign currency exchange translation adjustment 484 (5,868 ) (108 ) 23,790
Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of $0, $0, $0 and $0, respectively (6 ) 86 (159 ) 464
Total other comprehensive income (loss), net of tax 478 (5,782 ) (267 ) 24,254
Total comprehensive loss $(54,613 ) $(84,900 ) $(166,067 ) $(172,942 )

Basic and diluted net loss per ordinary share $ (0.21 ) $ (0.30 ) $ (0.62 ) $ (0.74 )
Weighted-average basic and diluted ordinary shares 266,203,656 266,141,431 266,168,856 266,136,518

Financial Results for the Period Ended September 30, 2026
Selected Consolidated Balance Sheet Data
(In thousands)

September 30, December 31,
2026
2025
Assets
Cash and cash equivalents $ 245,405 $ 104,132
Marketable securities – Available-for-sale debt securities $ 2,972 $ 196,578
Total current assets $ 366,784 $ 435,915
Total assets $ 523,059 $ 589,068
Liabilities and shareholders’ equity
Total current liabilities $ 98,647 $ 73,440
Total liabilities $ 495,663 $ 410,939
Total shareholders’ equity $ 27,396 $ 178,129

Conference Call
Management will host a conference call and webcast today at 8:30am EDT/1:30pm GMT to discuss the company’s financial results. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website at View Source

(Press release, Autolus, NOV 10, 2026, View Source [SID1234674552])

RECORDATI FIRST NINE MONTHS 2026: NET REVENUE +7.5%, EBITDA +7.7%, ADJUSTED NET INCOME +6.4%

On November 10, 2026 The Board of Directors of Recordati S.p.A. reported the interim financial statements as of September 30, 2026, representing additional voluntary financial reporting(6). The report was prepared using the assessment, measurement and recognition criteria prescribed by international accounting standards (IFRS). The Group’s Interim Report as of September 30, 2026 will be available within the legal deadline at the company’s offices and on the company’s website (www.recordati.com) and can also be viewed on the authorized storage system 1Info (www.1Info.it).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rob Koremans, Chief Executive Officer of Recordati, commented: "The performance in the first nine months of 2026 reflects the resilience of our business and the continued successful execution of our strategy. Our Rare Diseases franchise remains a key driver of growth, supported by strong momentum across our portfolio, particularly Isturisa in the U.S., and continued progress in advancing our pipeline. At the same time, our Specialty & Primary Care business continues to demonstrate resilience, supported by the strength of our established brands and disciplined commercial execution. As we approach the end of the year, we remain focused on delivering against our commitments, investing in our future growth opportunities and ensuring that we continue to make a meaningful difference to the lives of patients around the world."

Financial highlights

Consolidated net revenue for the first nine months of 2026 was € 2,103.7 million, up 7.5% or 9.4% on a like-for-like(3) basis at CER (+8.0% excluding Türkiye) versus the first nine months of 2025. This was driven, in particular, by the strong momentum from the Rare Diseases business. The adverse FX impact for the first nine months of 2026 was € 35.6 million (-1.8%), mainly driven by the devaluation of the U.S. dollar and the Turkish lira.

Rare Diseases revenue was € 928.2 million for the first nine months of 2026, up 18.7%, or 21.3% on a like-for-like(3) basis at CER as compared to the first nine months of 2025, driven by strong volume growth across the Endocrinology and Hema-Oncology franchises. The Endocrinology franchise achieved net revenue of € 389.8 million, an increase of 37.5%, reflecting continued growth of Isturisa (€ 285.9 million, +54.8%), driven by strong new patient uptake across geographies, particularly in the U.S., and growth of Signifor (€ 103.9 million, +5.1%). The Hema-Oncology franchise achieved net revenue of € 347.5 million, growing by 15.3%, reflecting the strong momentum of Enjaymo across geographies (€ 135.2 million, +30.0%), as well as growth of Qarziba (€ 125.5 million, +7.3%) and Sylvant (€ 74.4 million, +6.8%). The Metabolic franchise achieved net revenue of € 190.9 million, a decrease of 3.3%, with positive growth in the second and third quarters of 2026, and reflecting phasing of Carbaglu across geographies and positive one-offs in 2025 in France, and slightly lower demand of Panhematin in Brazil against a strong performance in the first nine months of 2025.

Specialty & Primary Care revenue was € 1,135.5 million for the first nine months of 2026, up 0.5% or 1.7% on a like-for-like(3) basis at CER as compared to the first nine months of 2025(7), reflecting continued in-market growth of the promoted portfolio (+8.4%(8)) and some expected one-off headwinds. In particular, the Cardiovascular franchise achieved net revenue of € 311.4 million, an increase of 0.4%, mainly reflecting the loss of the Cardicor license, offset by the growing contribution of Vazkepa and Livazo. The Urology franchise achieved net revenue of € 312.5 million, an increase of 1.0%, driven by the strong performance of Eligard benefiting from a competitor stock-out in Türkiye, as well as by local products, mostly offset by the one-off Tergynan re-launch in Russia in 2025. The Gastrointestinal franchise achieved net revenue of € 196.2 million, an increase of 2.1%, mainly driven by Procto-Glyvenol. The Cough & Cold franchise achieved net revenue of € 82.1 million, a decrease of 8.6% due to a weaker season in key markets.

EBITDA(1) was € 801.1 million for the first nine months of 2026, up 7.7% compared to the first nine months of 2025, with margin of 38.1% of net revenue. Strong revenue performance and the positive mix effect at the gross profit level was partially offset by a higher level of investments to support the U.S. expansion, primarily for Isturisa, the continued development of Enjaymo, ongoing geographic expansion in Rare Diseases as well as the launch of Vazkepa in Specialty & Primary Care.

Adjusted operating income(9) was € 642.2 million in the nine months of 2026, an increase of 8.6% versus the first nine months of 2025. This represents 30.5% of net revenue, compared with 30.2% in the prior year, supported by strong operating performance. Operating income was € 621.2 million in the first nine months of 2026, up 25.1% over the first nine months of 2025, when non-cash charges of € 62.5 million were posted, mainly due to the fair value revaluation of the inventory acquired as part of the acquisition of the Enjaymo rights. Non-recurring costs were € 21.0 million, compared with € 32.0 million in the first nine months of 2025, mainly reflecting the acceleration of the LTI Performance Share Plan triggered by the potential delisting of Recordati.

Financial expenses were € 83.2 million in the first nine months of 2026, up by € 15.9 million compared to the same period of the previous year, mainly due to net exchange rate losses of € 5.3 million as compared to exchange rate gains of € 10.9 million in the first nine months of 2025, with the variance mainly driven by the performance of the U.S. dollar. Lower interest expenses contributed a positive impact of € 2.4 million compared to the same period of the previous year, mainly due to lower net debt, while impact of hyperinflation was negative € 4.3 million compared to € 4.5 million in the first nine months of 2025.

Adjusted net income(2) was € 524.9 million, 25.0% of net revenue, up by 6.4% compared to the same period of 2025, benefitting from higher adjusted operating income, partly offset by higher financial expenses and tax rate. Net income was € 407.1 million, 19.4% of net revenue, an increase of 24.8% versus the prior year, reflecting higher operating income, despite the higher financial expenses and income tax rate versus the first nine months of 2025.

Free cash flow(4) was € 459.8 million for the first nine months of 2026, an increase of € 63.0 million versus the first nine months of 2025, driven primarily by higher EBITDA, while higher income tax paid were offset by a favorable impact of changes in other assets and liabilities.

Net debt(5) as of September 30, 2026 was € 1,697.8 million, or leverage around 1.6x EBITDA, compared to net debt of € 2,037.3 million on December 31, 2025.

Shareholders’ equity was € 2,339.9 million.

Pipeline Development

The osilodrostat (Isturisa) Phase IV study in patients with hypertension caused by hypercortisolemia due to Cushing’s syndrome was initiated in August 2026.

The Phase 2 trial evaluating pasireotide for the treatment of post-bariatric hypoglycemia met its primary endpoint with a dose-dependent and significant increase in glucose levels during a standardized meal test (p<0.02)(10). The Phase 3 development plan is expected to be finalized by the end of 2026.

On the basis of encouraging FDA feedback as well as early clinical evidence showing that sutimlimab, by targeting the classical complement pathway, can lead to a rapid and sustained platelet response in patients with immune thrombocytopenia (ITP) refractory to multiple lines of treatment, Recordati expects to advance sutimlimab into a pivotal registrational Phase 3 trial for the treatment of chronic ITP at the beginning of 2027.

The other lifecycle management programs are progressing in line with plans.

Corporate Development

On January 29, 2026, Recordati announced a collaboration and license agreement with Moderna to develop and commercialize worldwide mRNA-3927, an investigational product for the treatment of propionic acidemia (PA). Under the terms of the agreement, Moderna will continue to lead the development of mRNA-3927, in collaboration with Recordati, and if approved, Recordati will lead global commercialization. mRNA-3927 is a post proof-of-concept, investigational product aimed to restore propionyl-CoA carboxylase (PCC) enzyme activity in patients with propionic acidemia. If approved, this could be the first disease-modifying treatment option on the market for this severe disease. mRNA-3927 is currently being evaluated in a potential registrational clinical study. The target patient enrollment has been reached, with a data readout expected by the end of 2026.

On June 25, 2026, Recordati announced a license agreement with Ionis Pharmaceuticals, Inc. for exclusive development and commercialization rights to zilganersen, an investigational RNA-targeted medicine for the treatment of Alexander disease (AxD), in all countries outside the U.S. Recordati will be responsible for regulatory filings and commercialization outside the U.S., including country-specific support for early access pathways based on local regulations and access dynamics. Ionis will maintain sole commercial responsibility for zilganersen in the U.S. and will continue to lead development globally. Alexander disease is a rare, progressive and often fatal neurological disorder caused by mutations in the GFAP gene. The disease affects astrocytes, critical support cells in the brain, leading to progressive loss of neurological function, including mobility, independence, swallowing and breathing. There are currently no approved disease-modifying therapies for AxD.

Voluntary Tender Offer

On November 9, 2026, the offering period of the voluntary cash tender offer launched on Recordati by CVC Fund IX (through CVC Capital Partners IX Aggregator SCA SICAV-RAIF Sub-Fund 2) and GBL (through its controlled investment vehicle Black Mountain S.à r.l.), through Respighi BidCo S.p.A. (the "Offeror"), ended.

Based on the provisional results, the Offeror holds an aggregate shareholding representing approximately 91.451% of the Company’s share capital (approximately 92% of the Company’s share capital, taking also in account the treasury shares).

Upon confirmation of the provisional results, the Offeror will proceed to the squeeze-out of the remaining 16,881,530 shares, representing approximately 8% of the Company’s share capital, through the joint procedure pursuant to Articles 108, paragraph 2, and 111 of the Legislative Decree no. 58 of 24 February 1998, as subsequently amended and supplemented (the "CFA"), which will result in the delisting of Recordati shares from Euronext Milan. It is reasonable to expect that this procedure will be completed by the end of the month of November.

The final results of the reopening period will be announced by 7:29 a.m. on 16 November 2026, and the consideration for the shares tendered during the reopening period will be paid on 17 November 2026.

For additional information on the provisional results of the Offer following the reopening of the terms please refer to Press Release issued by Respighi BidCo S.p.A. on 9 November 2026 available on Recordati’s website at View Source where further information on the voluntary tender offer is also available.

Management and coordination

The Board of Directors also acknowledged that, following the settlement of the Offer, Recordati S.p.A. has become subject to the management and coordination of Respighi TopCo S.à r.l. pursuant to Articles 2497 et seq. of the Italian Civil Code, replacing Rossini Luxembourg S.à r.l. in such capacity.

Business outlook

The Group confirms its financial targets for full year 2026 as follows and expects to land in the upper end of the guidance ranges:

Net revenue between € 2,730 and € 2,800 million with FX headwind of ~-3.5%
EBITDA(1) between € 995 and € 1,030 million; margin of +/- 36.5% with FX headwind of ~-4.0%
Adjusted net income(2) between € 655 and € 685 million; margin of +/- 24.0%

The full year 2027 targets(11) remain unchanged, with strong organic growth complemented by bolt-on business development and M&A.

Interim dividend 2026
No interim dividend in view of the imminent squeeze-out and delisting

In light of the results of the Offer, the imminent squeeze-out of the minority shareholders and the resulting delisting of the Company’s shares from Euronext Milan, and considering that the Offer price of €53 per share is "cum dividend" (such that any interim dividend paid would be deducted from the Offer price and would therefore have no economic impact on the minority shareholders), the Board of Directors resolved not to approve the distribution of an interim dividend in respect of the 2026 financial year. Accordingly, the payment of the interim dividend indicated in the 2026 corporate events calendar (ex-dividend date 23 November 2026, payment date 25 November 2026) will not occur.

Conference Call

In light of the ongoing voluntary tender offer (VTO) process and Respighi’s current shareholding in Recordati, the Company will not hold a conference call in connection with its first nine months 2026 financial results. The presentation on the first nine months 2026 financial results will be made available at www.recordati.com under Investors/Company Presentations. The Investor Relations team remains available to address any questions through the usual communication channels.

(Press release, Recordati, NOV 10, 2026, View Source [SID1234674570])

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

On November 10, 2026 Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, reported that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial will evaluate INCA33890, Incyte’s investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have completed surgery and adjuvant chemotherapy (ACT), incorporating Signatera as both a primary and secondary endpoint. Following ACT, patients will undergo longitudinal testing with Signatera for up to 12 months, and those who test Signatera MRD-positive and have no evidence of radiographic disease may be eligible for enrollment and treatment in the study.

Natera’s clinical and real-world evidence, along with its expertise in MRD-guided clinical trial strategy and design, helped inform the study. Through the collaboration, Natera will also provide trial matching services to help identify patients for enrollment based on their Signatera MRD status and other eligibility criteria.

"We are excited by Incyte’s vision for this innovative trial, leveraging both our extensive real-world evidence and proven MRD capabilities," said Eric Matthews, General Manager, BioPharma, Natera. "Across a growing portfolio of TOMR studies, Signatera has been shown to enable early identification of patients at elevated risk of recurrence and supports enrollment into trials with treatment strategies that may alter the course of disease before radiographic progression occurs."

"Patients with colorectal cancer who remain MRD-positive after surgery and chemotherapy represent a population with substantial unmet need and a significantly elevated risk of recurrence," said Lois Erskine, Vice President and INCA 33890 Global Program Head, Incyte. "We look forward to the valuable insights this collaboration will enable as we work to advance this promising treatment and aim to improve outcomes for patients with CRC."

(Press release, Natera, NOV 10, 2026, View Source [SID1234674592])

BioNTech to Acquire US FDA Priority Review Voucher

On November 10, 2026 BioNTech SE (Nasdaq: BNTX, "BioNTech") reported that it has entered into an agreement to acquire a US Food and Drug Administration ("FDA") Priority Review Voucher ("PRV") from Scholar Rock, Inc. (Nasdaq: SRRK, "Scholar Rock") for a total cash consideration of $205 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A PRV grants FDA priority review for a single application, which reduces the target FDA review timeline and could lead to expedited approval. BioNTech intends to use the PRV to support a future filing of an asset in its late-stage oncology pipeline. The transaction is subject to customary closing conditions, including clearance under the Hart-Scott Rodino ("HSR") Antitrust Improvements Act.

(Press release, BioNTech, NOV 10, 2026, View Source [SID1234674553])